SEC Comment Letter 0000000000-22-013946 to Monopar Therapeutics (MNPR)
Monopar Therapeutics
Date: Dec. 28, 2022 · CIK: 0001645469 · Accession: 0000000000-22-013946
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268935
Letter
United States securities and exchange commission logo December 28, 2022 Chandler D. Robinson Chief Executive Officer Monopar Therapeutics Inc. 1000 Skokie Blvd., Suite 350 Wilmette, IL 60091 Re:Monopar Therapeutics Registration Statement on Form S-3 Filed December 21, 2022 File No. 333-268935 Dear Chandler D. Robinson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John J. Harrington
Show Raw Text
United States securities and exchange commission logo
December 28, 2022
Chandler D. Robinson
Chief Executive Officer
Monopar Therapeutics Inc.
1000 Skokie Blvd., Suite 350
Wilmette, IL 60091
Re:Monopar Therapeutics
Registration Statement on Form S-3
Filed December 21, 2022
File No. 333-268935
Dear Chandler D. Robinson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: John J. Harrington